Difference between revisions of "Mitoxantrone (Novantrone)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
|||
| (5 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
<br>Extravasation: [[irritant]] (usually), [[vesicant]] (rare) | <br>Extravasation: [[irritant]] (usually), [[vesicant]] (rare) | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is established ''(work in progress)''== | ==Diseases for which it is established ''(work in progress)''== | ||
| Line 21: | Line 21: | ||
**[[B-cell lymphoma of mucosa-associated lymphoid tissue]] | **[[B-cell lymphoma of mucosa-associated lymphoid tissue]] | ||
**[[Diffuse large B-cell lymphoma]] | **[[Diffuse large B-cell lymphoma]] | ||
| − | **[[Hodgkin lymphoma]] | + | **[[Classical Hodgkin lymphoma]] |
**[[Marginal zone lymphoma]] | **[[Marginal zone lymphoma]] | ||
*[[Prostate cancer]] | *[[Prostate cancer]] | ||
| Line 36: | Line 36: | ||
*1987-12-23: Initial FDA approval for the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes [[Acute_myeloid_leukemia|myelogenous]], [[Acute_promyelocytic_leukemia|promyelocytic]], monocytic, and erythroid acute leukemias. ''(Based on Arlin et al. 1990)'' | *1987-12-23: Initial FDA approval for the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes [[Acute_myeloid_leukemia|myelogenous]], [[Acute_promyelocytic_leukemia|promyelocytic]], monocytic, and erythroid acute leukemias. ''(Based on Arlin et al. 1990)'' | ||
*1996-11-13: Approved in combination with [[:Category:Steroids|corticosteroids]] as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory [[Prostate cancer | prostate cancer]]. ''(Based on CALGB 9182, CCI-NOV22, Moore et al. 1994)'' | *1996-11-13: Approved in combination with [[:Category:Steroids|corticosteroids]] as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory [[Prostate cancer | prostate cancer]]. ''(Based on CALGB 9182, CCI-NOV22, Moore et al. 1994)'' | ||
| − | + | ==History of changes in EMA indication== | |
| + | *1981-06-15: EURD | ||
==Also known as== | ==Also known as== | ||
*'''Generic name:''' mitozantrone | *'''Generic name:''' mitozantrone | ||
| Line 49: | Line 50: | ||
[[Category:Anthracenedione]] | [[Category:Anthracenedione]] | ||
| − | [[Category:Topoisomerase inhibitors]] | + | [[Category:Topoisomerase II inhibitors]] |
[[Category:B-cell acute lymphoblastic leukemia medications]] | [[Category:B-cell acute lymphoblastic leukemia medications]] | ||
| Line 57: | Line 58: | ||
[[Category:Diffuse large B-cell lymphoma medications]] | [[Category:Diffuse large B-cell lymphoma medications]] | ||
[[Category:Follicular lymphoma medications]] | [[Category:Follicular lymphoma medications]] | ||
| − | [[Category:Hodgkin lymphoma medications]] | + | [[Category:Classical Hodgkin lymphoma medications]] |
[[Category:MALT lymphoma medications]] | [[Category:MALT lymphoma medications]] | ||
[[Category:Mantle cell lymphoma medications]] | [[Category:Mantle cell lymphoma medications]] | ||
| Line 67: | Line 68: | ||
[[Category:FDA approved in 1987]] | [[Category:FDA approved in 1987]] | ||
| + | [[Category:EMA approved in 1981]] | ||
Latest revision as of 01:06, 29 June 2024
General information
Class/mechanism: Synthetic antineoplastic anthracenedione, intercalates into DNA, causing crosslinking and strand breaks. Mitoxantrone inhibits topoisomerase II, which helps to uncoil and repair damaged DNA. It also has been observed to interfere with RNA and has activity against resting and proliferating cells. In vitro, it has been observed to interfere with antigen presentation; inhibit B-cell, T-cell, and macrophage proliferation; and decrease secretion of interferon gamma, tumor necrosis factor-alpha (TNF-α), and interleukin-2 (IL-2).[1][2]
Route: IV
Extravasation: irritant (usually), vesicant (rare)
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]
Diseases for which it is established (work in progress)
- Non-Hodgkin lymphoma
Diseases for which it is used
- B-cell acute lymphoblastic leukemia
- Acute myeloid leukemia
- Acute promyelocytic leukemia
- Breast cancer
- Non-Hodgkin lymphoma
- Prostate cancer
- T-cell acute lymphoblastic leukemia
Diseases for which it was used
Patient drug information
- Mitoxantrone (Novantrone) patient drug information (Chemocare)[3]
- Mitoxantrone (Novantrone) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1987-12-23: Initial FDA approval for the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias. (Based on Arlin et al. 1990)
- 1996-11-13: Approved in combination with corticosteroids as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. (Based on CALGB 9182, CCI-NOV22, Moore et al. 1994)
History of changes in EMA indication
- 1981-06-15: EURD
Also known as
- Generic name: mitozantrone
- Brand names: Nitrol, Novantron, Novantrone
References
Categories:
- Drugs
- Intravenous medications
- Irritant
- Anthracenedione
- Topoisomerase II inhibitors
- B-cell acute lymphoblastic leukemia medications
- Acute myeloid leukemia medications
- Acute promyelocytic leukemia medications
- Breast cancer medications
- Diffuse large B-cell lymphoma medications
- Follicular lymphoma medications
- Classical Hodgkin lymphoma medications
- MALT lymphoma medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Prostate cancer medications
- T-cell acute lymphoblastic leukemia medications
- Chronic lymphocytic leukemia medications (historic)
- FDA approved in 1987
- EMA approved in 1981